Bavarian Nordic

Latest Headlines

Latest Headlines

Bavarian Nordic announces PhI data for new cancer vaccine candidate

Bavarian Nordic makes most of its money from its smallpox business, but it is working to expand its reach with moves in the cancer vaccine arena. Toward that end, the Danish company announced on Tuesday the results from a National Cancer Institute-sponsored Phase I study of its new cancer vaccine candidate, MVA-BN Brachyury.

J&J brings Ebola vaccine to trial in Sierra Leone

Just three weeks after it struck up a $28.5 million government partnership to advance its Ebola vaccine, Johnson & Johnson announced on Friday that it is starting a safety and immunogenicity trial in Sierra Leone for its Ebola candidate.

J&J's Janssen strikes four-year, $28.5M government partnership to advance Ebola vaccine

Johnson & Johnson's Janssen struck a four-year, $28.5 million government partnership to further the development of the Ebola jab on which Janssen is collaborating with Bavarian Nordic. Janssen awarded Bavarian Nordic $9 million in a subcontract, the latter announced Tuesday.

Bavarian Nordic to start PhI trial of RSV jab

Things are heating up in the race for a respiratory syncytial virus (RSV) vaccine.Novavax reported Phase II results for its investigational vaccine just a week ago, and now, Danish biotech Bavarian Nordic is starting a Phase I trial of its candidate.

Kerrisdale Capital keeps its foot on Bavarian Nordic's throat with further discussion of short thesis

Kerrisdale Capital is maintaining the pressure on Bavarian Nordic. Having precipitated a 13% drop in the stock of Bavarian Nordic in the 10 days since it unveiled its short thesis, the hedge fund is now holding a follow-up call to expand on its theory that the Danish drugmaker is a busted flush.

Bavarian Nordic lands in crosshairs of short-selling campaign

As it works to bring its prostate cancer vaccine Prostvac to market and expand its smallpox vaccine business, Danish vaccine maker Bavarian Nordic this week encountered a new set of challenges. It's the target of a short-selling campaign.

Shares in Bavarian Nordic dip after short seller posts broadside against its cancer vaccine

Hedge fund Kerrisdale Capital has orchestrated an attack on Bavarian Nordic, the centerpiece of which is a 52-page report that argues the valuation of the Danish drugmaker is based on misplaced faith in the likelihood of its cancer vaccine succeeding in Phase III.

Bavarian Nordic starts PhII of Prostvac in early-stage cancer

Looking to expand its potential market for prostate cancer immunotherapy candidate Prostvac, Bavarian Nordic has announced that it's beginning a Phase II trial for its vaccine in early-stage prostate cancer, representing another possible avenue to broaden the candidate's reach.

GSK and J&J/Bavarian Nordic take Ebola candidates to Senegal, Europe

Although the waning Ebola outbreak had Big Pharmas struggling to find volunteers for their Ebola vaccine trials, two new Phase II trials are going forward. GlaxoSmithKline will take its candidate to Senegal, while Johnson & Johnson and partner Bavarian Nordic will test their vaccine in France and the U.K.

U.S. government orders additional $133M of Bavarian Nordic's smallpox vaccine

On Tuesday, the U.S. government placed a large new order for Bavarian Nordic's smallpox vaccine while the company continues work to improve its formulation to offer more stockpiling flexibility.